Skip to content

Wuxi-Backed Chinese Biotech Cstone Considers Sale

  • Cstone working with Goldman to sound out potential buyers
  • Other Chinese, global drugmakers could be interested
Updated on

Cstone Pharmaceuticals, a Hong Kong-listed biotechnology company focused on developing cancer drugs, is exploring strategic options including a sale of the business, according to people familiar with the matter.

The Chinese firm, whose investors include a fund backed by WuXi AppTec Co., is working with Goldman Sachs Group Inc. to help sound out interest from prospective buyers, the people said. It’s considering options including the sale of a controlling stake in the company, the people said, asking not to be identified because the matter is private.